key: cord-0849201-f7rjziap
authors: Martín Ramírez, Alexandra; Zurita Cruz, Nelly Daniela; Gutiérrez-Cobos, Ainhoa; Rodríguez Serrano, Diego Aníbal; González Álvaro, Isidoro; Vallejo, Emilia Roy; de Frutos, Sara Gómez; García-Rodrigo, Leticia Fontán; Cardeñoso Domingo, Laura
title: Evaluation of two RT-PCR techniques for SARS-CoV-2 RNA detection in serum for microbiological diagnosis
date: 2021-12-12
journal: J Virol Methods
DOI: 10.1016/j.jviromet.2021.114411
sha: f244fa5143a062369d823db09d03ef5cdf003e9e
doc_id: 849201
cord_uid: f7rjziap

Presence of SARS-CoV-2 RNA in serum (viremia) of COVID-19 patients has been related to poor prognosis and death. The aim of this study was to evaluate both the ability to detect viremia in COVID-19 patients of two commercial reverse real-time-PCR (rRT-PCR) tests, Cobas® and TaqPath™, comparing them with a gold standard method, and their implementation in microbiology laboratories. This retrospective cohort study included 303 adult patients (203 diagnosed with COVID-19 and 100 non-COVID-19 patients) admitted to a tertiary hospital, with at least one serum sample collected within the first 48 hours from admission. A total of 365 serum samples were included: 100 from non-COVID-19 patients (pre-pandemic and pandemic control groups) and 265 from COVID-19 patients. Serum samples were considered positive when at least one target was detected. All patients in control groups showed negative viremia. Cobas® and TaqPath™ tests showed specificity and Positive Predictive Value over 96%. Nevertheless, sensitivity (53.72 and 73.63, respectively) and Negative Predictive Value (64.78 and 75) were lower. Viremia difference between ICU and non-ICU patients was significant (p ≤ 0.001) for both techniques. Consequently, SARS-CoV-2 viremia detection by both rRT-PCR tests should be considered a good tool to stratify COVID-19 patients and could be implemented in microbiology laboratories.

This retrospective cohort study was conducted with 303 adult patients admitted to La Princesa University Hospital, a tertiary level hospital in Madrid (Spain). Fifty patients admitted to the hospital during November 2019 with respiratory symptoms were considered the pre-pandemic control group (median age 73.5 years [interquartile range, ] and 50% male). Two hundred fifty-three patients were admitted to the hospital between March 1 st and May 31 th with at least one serum sample collected within the first 48 hours from admission. Fifty out of these 253 patients had negative COVID-19 PCR results in nasopharyngeal swabs, and they were considered the pandemic control group (median age 69 years and 64% male). The remaining 203 patients (median age 64 years and 68.5% male) had SARS-CoV-2 infection, confirmed by a positive PCR on a nasopharyngeal swab sample. These patients were considered the COVID-19 group. Eighty-nine of them (median age 65 years and 71.3% male) were admitted to the Intensive Care Unit (ICU), while 114 (median age 64 years and 66.4% male) were admitted to the general ward.

Serum samples were collected through routine clinical practice. Additional serum samples were collected from several patients (50) during their hospital admission as part of their routine management. A total of 365 serum samples were included in this study: 50 serum samples from the pre-pandemic control group, 50 from the pandemic control group and 265 from the COVID-19 group ( Figure 1 ). All samples were stored at -20 ºC until they were tested.

J o u r n a l P r e -p r o o f 

Serum samples were tested with two rRT-PCR assays: cobas® SARS-COV-2 test (cobas® test), a qualitative assay for detection of SARS-CoV-2 RNA; and TaqPath™ COVID-19 CE-IVD RT-PCR Kit (TaqPath™ test), a multiplex RT-PCR assay for qualitative detection of SARS-CoV-2 nucleic acids. Both are used for routine detection of SARS-CoV-2 in nasopharyngeal swab samples at our hospital. J o u r n a l P r e -p r o o f 6 The analysis was performed only once for each molecular method because sample volumes were limited.

Test assays with all the three rRT-PCR methods were carried out using 400 µL of serum, previously treated for virus inactivation with lysis buffer.

This assay detects a fragment of the SARS-COV-2 specific orf-1ab region, and a conserved region of the structural envelope e gene, for pan-sarbecovirus detection. Test was performed by cobas® 6800 System (Roche Diagnostics, USA), an automatic platform for nucleic acid extraction and RT-PCR amplification and detection. An initial volume of 400µl of serum, inactivated with 400µl of lysis reagent, was processed according to manufacturer's indications, following the same protocol used for SARS-CoV-2 detection in respiratory samples. Results were analyzed and interpreted automatically by the cobas® 6800/8800 Software version 1.02.12.1002.

A previous nucleic acid extraction from 400 µl of serum, inactivated with 400µ of NUCLISENS® easyMAG® Lysis Buffer (Biomérieux), was performed by the automatic eMAG® Nucleic Acid Extraction System (Biomerieux, France) according to manufacturer's indications, obtaining purified RNA in 60 µL of elution buffer. This eluate was used for SARS-CoV-2 detection by both TaqPath™ test and Gold Standard Method.

TaqPath™ test detects three specific SARS-CoV-2 genomic regions (orf-1ab, s, and n genes) and it was carried out using 5 µL of purified RNA. 

Detection of at least one target was considered as a positive result.

Evaluation of viremia in patients was carried out considering only the results obtained from their first serum sample.

Results obtained from all 365 collected samples were analyzed for assessment of the techniques.

Statistical analysis was performed using SPSS 25.0 (IBM Corp., USA). Continuous and categorical variables were presented as median (IQR) and n (%), respectively. 

Viremia detection in patients of the COVID-19 group showed the following results: The cobas® test detected viremia in 50.2% of included patients, showing 65.2% and 38.6 % positive viremia detection for ICU and non-ICU admitted patients, respectively. The TaqPath™ test detected viremia in 62.6% of all included patients, with viremia detection in 75.3% of patients admitted to ICU, and in 52.6% of those patients who did not require ICU admission. For both techniques, differences of viremia detection between the ICU and non-ICU patients were significant (p≤0.001). Results are shown in Table 1 .

Furthermore, the gold standard assay was able to detect presence of SARS-Cov-2 RNA in 80.8% of patients, with the following distribution: 85.4% and 77.2% for ICU and non-ICU patients, respectively. No significant differences were found between both groups (p=0.14). Viremia was not detected by any of the three techniques in any of the patients of the control groups. Table 3 shows the concordance of positive and negative results obtained by TaqPath™ and Cobas® tests with those found with the gold standard method. 

To our knowledge, this is the first study assessing two commercial rRT-PCR assays for SARS-CoV-2 RNA detection in serum samples. The goal of this study was to provide clinicians with a useful tool for the J o u r n a l P r e -p r o o f management of COVID-19. Although these commercial assays have not been validated for their use in serum or plasma samples, the extraction methods performed in this study are commonly used for other viruses in serum or plasma samples (Barreiro et al., 2015; Loens et al., 2007; Wirden et al., 2017) .

The preferred method for SARS-CoV-2 detection is rRT-PCR of upper respiratory tract samples, collected by nasopharyngeal and oropharyngeal swabs or, in some cases, lower respiratory tract samples (Pascarella et al., 2020) . However, SARS-CoV-2 has been detected in multiple types of samples such as saliva, stool, plasma and serum Zhang et al., 2020) . Detection of SARS-CoV-2 RNA in serum samples has been related to progression to critical disease and death (Hagman et al., 2020; Xu et al., 2020) , as well as to a cytokine storm syndrome characterized by several inflammation and severe disease markers, such as lower absolute lymphocyte counts and higher levels of both C-reactive protein and IL-6 (Fajnzylber et al., 2020) . Moreover, a recent study showed that prevalence of SARS-CoV-2 viremia is significantly higher in hospitalized COVID-19 patients with detectable troponin and myocardial injury (Siddiqi et al., 2020) . However, most of the studies use in-house or commercial methods for SARS-CoV-2 detection that are not validated in serum or plasma samples (Hagman et al., 2020; Xu et al., 2020) .

In our study, viremia percentages obtained with the two rRT-PCR assays showed significant differences (p≤0.001) between ICU patients and patients admitted to the general ward, thus supporting previous studies indicating that presence of SARS-CoV-2 RNA in serum samples is more common in critical patients and could be considered a prognostic indicator (Fajnzylber et al., 2020; Hagman et al., 2020; Hogan et al., 2020; Veyer et al., 2020) . Accordingly, the probability that samples with e gene amplification without any other target are positive for other sarbecoviruses is very low; in addition, other reports also considered them as positives (Wirden et al., 2017) . It is difficult to elucidate the cause of these false negative results, as we used commercial rRT-PCR kits whose design is not available for customers. Nevertheless, differences in the number of targets, and possibly in the sequence or the size of the amplicons, may cause differences in sensitivity between the techniques.

Moreover, the cobas® test is performed in the automatic close cobas® 6800 system, making more difficult to elucidate the nature of discrepancies. A possible explanation is that these samples had low viral loads, decreasing the sensitivity of the assessed techniques. Also, the volume of eluted RNA added to the PCR reaction could have an influence since double volume is used for the gold standard method compared with the TaqPath™ test.

Regarding their implementation in clinical practice, both techniques can be easily introduced in the microbiology laboratory for the diagnosis of COVID-19 in serum samples and they can be performed along with SARS-CoV-2 detection in respiratory samples. The TaqPath™ test is more suitable to perform a small number of determinations at a time, while the cobas® test should be more useful to analyze a high number of samples.

The present study has some limitations. First, the intrinsic analytical variability of PCR may have exerted an influence on the results. Another limitation is the absence of significant differences between the percentage of viremia in ICU and non-ICU groups with the gold standard method, which may be due to a higher sensitivity in the detection of lower viral loads with this technique, which could lead to lower specificity. Finally, the type of sample used in this study is serum. Although serum samples are accepted in the analysis of viremia, the samples commonly used in most microbiology laboratories are plasma samples.

In conclusion, this study shows that cobas® SARS-CoV-2 Test and TaqPath™ COVID-19 CE-IVD RT-PCR Kit could be useful for detecting SARS-CoV-2 viremia in serum of diagnosed COVID-19 patients.

For good test performance both techniques require detection of at least one target, while the TaqPath™ assay additionally needs a Ct value under 37. A positive viremia result may help managing COVID-19 patients, since viremia has been recently related to bad prognosis and mortality in these patients (Fajnzylber et al., 2020; Hagman et al., 2020; Siddiqi et al., 2020; Xu et al., 2020) . In addition, these techniques are easy to incorporate in the Microbiology laboratory routine practice for SARS-CoV-2 detection.

Finally, early detection of SARS-CoV-2 viremia could help to stratify COVID-19 patients facilitating different treatment strategies (Fajnzylber et al., 2020; Hagman et al., 2020; Patterson et al., 2021) .

A. Martín Ramírez: methodology, formal analysis, investigation, writing.

N. D. Zurita Cruz: methodology, formal analysis, investigation, writing.

A. Gutiérrez Cobos: methodology, writing. D. A. Rodríguez Serrano: resources, writing.

J o u r n a l P r e -p r o o f

Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C

Antibody response and viraemia during the course of severe acute respiratory syndrome (SARS)-associated coronavirus infection

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Novel coronavirus: where we are and what we know

RNAemia Corresponds to Disease Severity and Antibody Response in Hospitalized COVID-19 Patients

The Massachusetts Consortium for Pathogen Readiness, 2020. SARS-CoV-2 viral load is associated with increased disease severity and mortality

SARS-CoV-2 RNA in serum as predictor of severe outcome in COVID-19: a retrospective cohort study

RNAemia and Association With Severe Disease

Detection of COVID-19: A review of the current literature and future perspectives

Evaluation of NucliSens easyMAG for Automated Nucleic Acid Extraction from Various Clinical Specimens

COVID-19 diagnosis and management: a comprehensive review

CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14

Novel Coronavirus (2019-nCoV) Nucleic Acid Diagnostic Kit (PCR-Fluorescense Probing) Instructions for use

Increased Prevalence of Myocardial Injury in Patients with SARS-CoV-2 Viremia

ThermoFisher Scientific, 2020. TaqPath TM COVID-19 CE-IVD RT-PCR Kit INSTRUCTIONS FOR USE

Consistent Detection of 2019 Novel Coronavirus in Saliva

Highly sensitive quantification of plasma SARS-CoV-2 RNA shelds light on its potential clinical value

Coronavirus disease (COVID-19) -World Health Organization [WWW Document

Severe Acute Respiratory Syndrome) [WWW Document

Multicenter comparison of the new Cobas 6800 system with Cobas Ampliprep/Cobas TaqMan and Abbott RealTime for the quantification of HIV, HBV and HCV viral load

Relationship Between serum SARS-CoV-2 nucleic acid(RNAemia) and

COVID-19 Patients: A Cohort Study. Clinical Infectious Diseases ciaa1085

Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes